1. Improving Safety, Efficiency and RegulatoryCompliance Via Asset Documentation IntegrityDavid Blain McLaren Software 2. Agenda•About McLaren Software•The Asset Lifecycle•Some…

1. Valuing Oncology Assets:Strategies in an evolving clinical andcommercial landscapeMay 23, 2012 2. Many Thanks to the Event Organizers and Sponsors! Adam Bristol (Aquilo…

1. Abigail, Ezekiel, and Freireich Mike Martin, MD My last Grand Rounds 12/19/8 2. CAVEAT 1:MY ROLE IN THIS PRESENTATION IS TO BE IMPARTIALCAVEAT 2:WITHOUT YOUR COMMENTS,…

Slide 1Off-Label Communications and the Public Health Presentation to the Pharmaceutical Compliance Forum November 8, 2007 Paul E. Kalb, M.D., J.D. With appreciation for…

Slide 1© FIMM - Institiute for Molecular Medicine Finlandwww.fimm.fi High Throughput Biomedicine Unit (HTB) at FIMM Technology Centre Slide 2 www.fimm.fi FIMM Technology…

1. Re-Engineering Early Phase Cancer DrugDevelopment: Decreasing the Time from Novel Target to Novel TherapeuticJames H. Doroshow, M.D. Deputy Director for Clinical &…

1. CRIMINAL PROSECUTIONS:PATIENT SAFETYPartnership for Safe Medicines Interchange 2014September 18, 2014Newseum, Washington, D.C.Moderator: Linda I. MarksSenior Litigation…

1. CONTROLLING THE KNOWN VARIABLES Strategies for solving the operational challenges of oncology clinical trials EXECUTIVE BRIEF 2. The Promise of Personalized Medicine •…

ONCOLOGY DRUGS: THE JOURNEY FROM MANUFACTURER TO END USER Dr. SALMAH BAHRI Director of Pharmacy Enforcement Pharmaceutical Services Division Ministry of Health Malaysia INTRODUCTION…

1. Ed Schnipper, M.D 2. Cancer Still a Major Problem • 600,000 deaths per year in US • 1,500 per day 3. Progress has been made • People living longer with cancer •…